Projects overview

Sort by

Toggle all information

ADAPTED | Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development - Sofia ref.: 115975

01-10-2016

-

30-09-2020

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-06 From ApoE biology to validated Alzheimer’s disease targets

PHAGO | Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976

01-11-2016

-

30-04-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-03 Inflammation and AD: modulating microglia function – focussing on TREM2 and CD33

AMYPAD | Amyloid imaging to Prevent Alzheimer’s Disease – Sofia ref.: 115952

01-10-2016

-

30-09-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-04 Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)

PREFER | Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966

01-10-2016

-

31-05-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-01 Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and Health Technology Assessment bodie

MOPEAD | Models Of Patient Engagement for Alzheimer’s Disease - Sofia ref.: 115985

01-10-2016

-

31-12-2019

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-05 Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease: Phased expansion study
Powered by Chris Decubber BV